Global Intranasal Corticosteroids Market Snapshot

According to Future Market Insights research, during the projected period, the global Intranasal Corticosteroids Market is expected to grow at a CAGR of 5.0%. The market value is projected to increase from USD 6.8 Billion in 2023 to USD 11.2 Billion by 2033. The intranasal corticosteroids market was valued at USD 6.5 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 4.8% in 2023.

Market Outlook:

Data Points Market Insights
Market Value 2022 USD 6.5 Billion
Market Value 2023 USD 6.8 Billion
Market Value 2033 USD 11.2 Billion
CAGR 2023 to 2033 5.0%
Market Share of Top 5 Countries 54.1%
Key Market Players Merck & co., GlaxoSmithKline, AstraZeneca, Sanofi, Perrigo Co., Teva Pharmaceutical Industries, Glenmark Pharmaceuticals, Mylan, Novartis, Pfizer, Pharmascience

Nasal steroid sprays are a type of medication that delivers corticosteroids directly into the nasal passages to alleviate symptoms associated with nasal allergies, including sneezing and a runny nose.

These sprays offer effective relief from hay fever and other nasal allergies, often serving as a viable alternative to oral allergy medications. It usually takes a few days of consistent use for the sprays to take effect. To maintain ongoing relief, it is important to use them daily throughout the allergy season.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Intranasal Corticosteroids Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The market value for intranasal corticosteroids expanded at a CAGR of close to 4.9% between 2017 and 2022. The intranasal corticosteroids market is around 32.4% of the overall USD 20.2 Billion global allergy treatment market in 2022.

The global market for intranasal corticosteroids experienced growth over past few decades driven by the increased prevalence of condition like allergic rhinitis and Chronic Obstructive Pulmonary Disease (COPD).

This increased prevalence has impacted infants, young children, and the elderly population suffering from these conditions. Most corticosteroids used are for treatment of seasonal allergic rhinitis caused due to aeroallergen.

Companies have been constantly working towards development of products to treat allergy related conditions which are effective yet cost-efficient.

  • In 2012, Nippon Shinyaku Co., Ltd. launched a dry powder type steroid nasal spray called 'Erizas Nasal Powder 200µg 28-metered spray' in Japan. This innovative product was specifically designed to effectively treat allergic rhinitis.
  • The product being referred to is the inaugural dry powder steroid nasal spray available in Japan for once-daily use.

This particular nasal spray has the capability to alleviate three common symptoms associated with allergic rhinitis, namely sneezing, nasal discharge, and nasal congestion.

As a result of these advantageous qualities, there has been a notable rise in the demand for intranasal corticosteroids.

What are the Key Opportunities for the Intranasal Corticosteroids Manufacturers?

Using a corticosteroid spray consistently on a daily basis is the most effective way to experience its benefits. To reduce symptoms during pollen season, it is recommended to start using the spray at the beginning of the season.

It is worth mentioning that nasal corticosteroid sprays are generally safe for adults, and there are specific types that are also safe for children aged 2 and older. Pregnant women can also use corticosteroid sprays safely, but it is important for them to consult with their healthcare provider to choose the options with the best safety record during pregnancy.

This ensures that a wider population can benefit from the use of intranasal corticosteroids worldwide.

Prominent companies are actively pursuing acquisitions and expanding their operations to strengthen their product offerings and reach a broader customer base.

  • In July 2019, Berry Global Group, Inc. acquired RPC Group Plc (RPC) at USD 6.5 billion. This revolutionary merger cements its position as one of the world's largest plastic packaging firms.

The above factors are likely to drive the global market in next few years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining the Demand for the Intranasal Corticosteroids?

Although all intranasal corticosteroids (INCSs) used for treating allergic rhinitis (AR) are generally considered safe and effective, variations in potency, molecular structure, and physicochemical and pharmacokinetic properties can lead to differences in their clinical effectiveness and safety profiles.

Some common side effects associated with intranasal corticosteroids include headache, nausea and vomiting, drowsiness, light-headedness, palpitations, loss of taste, wheezing, nosebleeds (epistaxis), nasal ulceration, irritation of the nose and throat (nasopharyngeal irritation), musculoskeletal pain, immunosuppression, and an increased risk of infections.

  • A significant number of patients did not adhere to the prescribed instructions for taking their INCS medication, indicating that the quality of administration can be deemed inadequate for numerous patients.

However, patients with low incomes, especially in developing countries, find it difficult to afford inhaled and intranasal corticosteroids. As a result, they often have no choice but to rely on less effective oral medications.

Country-wise Insights

Why is USA a Prominent Market for Intranasal Corticosteroids s in Asia Pacific region?

The USA leads the North America market contributing around USD 1.9 Billion in 2022.

Prevalence of allergies in the United States is relatively high, with millions of individuals suffering from seasonal and perennial allergies each year. The accessibility and availability of intranasal corticosteroid medications in the USA market contribute to their increased usage.

Moreover, healthcare professionals in the USA are well-informed about the benefits of intranasal corticosteroids and frequently prescribe them to patients who require allergy relief.

In the United States, there are currently nine branded Intranasal Corticosteroid products available. Among them, Nasacort Allergy 24HR (triamcinolone acetonide) and Flonase Allergy Relief (fluticasone propionate) are available over the counter.

Drug manufacturers are actively working to maximize the therapeutic effects of corticosteroid therapy while minimizing potential systemic adverse effects and improving patient adherence.

Overall, these factors contribute to the higher usage of intranasal corticosteroids in the United States.

What Makes the China a Large Market for Intranasal Corticosteroid fixation?

In 2022, the China held a dominant share of in the East Asia market and contributed around USD 466.0 Million.

  • The prevalence of allergic rhinitis (AR) is estimated to range from 10% to 40% globally, and in China, it was reported to be between 11.1% and 17.6% from 2005 to 2011, as per National Institute of Health study published in 2023.

The increasing urbanization and adoption of Westernized lifestyles in developing countries, along with rapid economic growth, have contributed to a rising trend of AR in recent decades. The prevalence of AR in China varies widely. Additionally, the impact of air pollution and climate change on respiratory disorders cannot be disregarded.

  • A genetic epidemiologic study conducted in Jiangsu Province, involving 23,825 families, found that the heritability of AR was 81.86% across three generations. Research published in Allergy, Asthma & Immunology Research 2019, has indicated that higher levels of air pollution during oak pollen season could potentially increase the occurrence of allergic airway disease in individuals who are sensitive to allergens. This is because the presence of air pollutants may contribute to the greater availability of airborne pollen allergens, thus exacerbating the allergic response.

What Makes India a Highly Lucrative Market for Intranasal Corticosteroids?

India holds nearly 6.7% market share in the global market in 2022. India is the lucrative market region in the South Asian market in revenue terms in 2022.

Indian subcontinent has witnessed a rise in allergic rhinitis and asthma cases over the past few decades.

  • The Lancet Global Health Journal-2022, estimated that globally, around 300 million people suffer from asthma, with 37.9 million of them residing in India.
  • As per National institute of Health, 2018, a study conducted in India revealed that the prevalence of allergic rhinitis was 11.3% among children aged 6-7 years and 24.4% among children aged 13-14 years.

India, on a global scale, faces one of the significant levels of air pollution, primarily caused by fossil fuels, vehicular emissions, and biomass. Additionally, the use of incense, mosquito coils, and dhoop sticks contributes significantly to indoor pollution. All these factors cumulatively is expected to boost the global market for intranasal corticosteroids market in India.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which form of dosage is more prevalent in intranasal corticosteroid market?

The global market for intranasal sprays reached a substantial value of USD 4.7 Billion in 2022.

Nasal sprays are liquid medications that are administered by spraying them into the nose. They are specifically designed to alleviate discomfort and congestion caused by allergies. Nasal sprays come in two types of containers: pressurized canisters and pump bottles.

Some commonly known examples of nasal sprays include Naselin Nasal Spray, Astelin, Astepro, Nazal Spray, Vicks Ultra Fine Mist, Otrivin Spray, and Sinarest Spray.

Why Allergic Rhinitis is the Leading Intranasal Corticosteroids in drug type?

During year 2022, Allergic rhinitis accounts for around 58.1% of the global market share. Intranasal corticosteroid (INCS) therapy is considered the preferred treatment option for allergic rhinitis (AR) as it effectively inhibits the degranulation of mast cells.

While these sprays are generally safe to use, they are not typically recommended as the first-line therapy for allergic rhinitis due to their lower effectiveness in relieving symptoms compared to antihistamines or intranasal corticosteroids. Additionally, their dosing schedule of three or four times daily can be inconvenient.

Which segment of Drug Corticosteroids is Aiding the Global Market to Propel?

Fluticasone Propionate accounts for 25.3% of the global market share in 2022.

Fluticasone Propionate helps reduce airway inflammation, thus improving breathing followed by reduced symptoms like coughing, shortness of breath and wheezing. It is also available as a nasal spray for the treatment of allergic rhinitis.

Fluticasone Propionate is considered an effective and commonly prescribed medication for respiratory conditions, and it is available in various brand names and forms. However, it should only be used under medical supervision and as prescribed by a healthcare professional.

Which Distribution Channel is Benefiting the Global Market?

Retail pharmacies captured a significant market share of around 31.7% in 2022. Retail pharmacies have established a strong presence with numerous conveniently located branches in various neighbourhoods and communities.

This widespread accessibility ensures that customers can easily purchase nasal corticosteroids without the need to travel long distances or wait for delivery.

Secondly, these pharmacies are staffed with well-trained pharmacists who are capable of providing valuable guidance and recommendations to customers regarding the use of nasal corticosteroids. This personalized advice instils confidence in customers and empowers them to make informed decisions about their healthcare.

Competitive Landscape

In the market for intranasal corticosteroids, key players are implementing various strategies to increase their sales and generate revenue.

  • Novartis International, obtained FDA approval in December 2020 for their supplemental Biologics License Age Group (sBLA) for Xolair® (omalizumab), which is used as an add-on maintenance treatment for nasal polyps in adult patients who have not responded well to nasal corticosteroids. Covis Pharma.

Bayer Healthcare LLC received FDA approval on June 17, 2021, for the nonprescription use of Astepro. This approval allows allergy sufferers to use the nasal sprays without the assistance of a healthcare provider when needed.

Similarly, recent developments related to the company’s manufacturing the Intranasal Corticosteroids have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as Per Intranasal Corticosteroids Industry Analysis

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2017 to 2022
Market Analysis USD Million for Value
Key Regions Covered North America; Latin America; Europe; South Asia; East Asia; Oceania; and MEA
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa.
Key Market Segments Covered Indication, Dosage Form, Drug, Distribution Channel, Region
Key Companies Profiled Merck & co.; GlaxoSmithKline; AstraZeneca; Sanofi; Perrigo Co.; Teva Pharmaceutical Industries; Glenmark Pharmaceuticals; Mylan; Novartis; Pfizer; Pharmascience
Report Coverage Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing Available upon Request

Key Market Segments Covered in the Intranasal Corticosteroids Industry Research

By Drug:

  • Fluticasone Propionate
  • Budesonide
  • Beclomethasone Dipropionate
  • Mometasone Furoate
  • Triamcinolone Acetonide
  • Ciclesonide
  • Flunisolide
  • Tixocortol

By Indication:

  • Allergic Rhinitis (AR)
    • Seasonal AR
    • Perennial AR
  • Non-Allergic Rhinitis (NAR)
    • Infectious NAR
    • Vasomotor NAR
    • Atrophic NAR

By Dosage Form:

  • Intranasal Drops
  • Intranasal Sprays

By Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

Which industry is the key consumer of Intranasal Corticosteroids Market?

The primary consumer for Intranasal Corticosteroids is the allergy and asthma industry.

What is the Intranasal Corticosteroids market outlook in the United States?

The United States is poised to stay attractive, projecting a USD 1.5 billion market by 2033.

What is the current market valuation of the Intranasal Corticosteroids Market?

The market is estimated to secure a valuation of USD 6.8 billion in 2023.

How big will the Intranasal Corticosteroids Market?

The market is estimated to reach USD 11.2 billion by 2033.

Which end-use industry holds lucrative opportunities in the market?

The allergy and asthma sector holds high revenue potential.

Table of Content
  • 1. Executive Summary
  • 2. Market Overview
  • 3. Key Market Trends
  • 4. Value Added Insights
  • 5. Market Background
  • 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
  • 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug
    • 7.1. Fluticasone Propionate
    • 7.2. Budesonide
    • 7.3. Beclomethasone Dipropionate
    • 7.4. Mometasone Furoate
    • 7.5. Triamcinolone Acetonide
    • 7.6. Ciclesonide
    • 7.7. Flunisolide
    • 7.8. Tixocortol
  • 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
    • 8.1. Allergic Rhinitis (AR)
      • 8.1.1. Seasonal AR
      • 8.1.2. Perennial AR
    • 8.2. Non-Allergic Rhinitis (NAR)
      • 8.2.1. Infectious NAR
      • 8.2.2. Vasomotor NAR
      • 8.2.3. Atrophic NAR
  • 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Dosage Form
    • 9.1. Intranasal Drops
    • 9.2. Intranasal Sprays
  • 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    • 10.1. Hospitals
    • 10.2. Retail Pharmacies
    • 10.3. Drug Stores
    • 10.4. Online Pharmacies
  • 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
    • 11.1. North America
    • 11.2. Latin America
    • 11.3. Europe
    • 11.4. East Asia
    • 11.5. South Asia
    • 11.6. Oceania
    • 11.7. Middle East and Africa
  • 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
  • 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
  • 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
  • 15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
  • 16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
  • 17. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
  • 18. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033
  • 19. Market Structure Analysis
  • 20. Competition Analysis
    • 20.1. GlaxoSmithKline
    • 20.2. AstraZeneca
    • 20.3. Sanofi
    • 20.4. Perrigo Co.
    • 20.5. Teva Pharmaceutical Industries
    • 20.6. Glenmark Pharmaceuticals
    • 20.7. Mylan
    • 20.8. Novartis
    • 20.9. Pfizer
    • 20.10. Pharmascience
  • 21. Assumptions and Acronyms Used
  • 22. Research Methodology
Recommendations

Healthcare

Nasal Antihistamines Market

June 2023

REP-GB-13708

315 pages

Healthcare

Nasal Allergy Treatment Market

April 2023

REP-GB-17114

342 pages

Healthcare

Nasal Sprays Market

January 2023

REP-GB-13112

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Intranasal Corticosteroids Market

Schedule a Call